Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Exactech Inc.
A financing round that was significantly oversubscribed by new and existing investors will help advance the Oxford-headquartered biotech's exosome therapeutics into the clinic and expand its technology platform.
Lantern, Avidity, Generation Bio and Vaxcyte launched initial public offerings during the second week of June as biopharma continues to intrigue IPO investors. Also, Blackstone invested $350m in Reata's bardoxolone and Checkmate’s $85m series C led recent VC deals.
Public Company Edition: After an initial hit to valuations from COVID-19, massive amounts of money have been raised by drug developers, such as argenx with a $862.5m stock sale. However, only two IPOs launched in the US in May, including ADC with a $267m offering.
A new COVID-19 vaccine dream team, updated trial results on remdesivir, and a rough first quarter for big pharma stocks. In addition to our daily in-depth coverage of key regulatory events relating to the coronavirus pandemic, these three topics are among a selection of brief insights we’re bringing you on biopharma commercial activities.
- Contract Manufacturing Organization
- Implantable Devices
- Surgical Equipment & Devices
- Other Names / Subsidiaries
- Blue Ortho SAS
- Exactech Australia Pty Ltd
- TPG Capital
- XpandOrtho, Inc.
- Exactech Italia